Review of modern methods of treating vitiligo-Reference-Cited by-同舟云学术

Review of modern methods of treating vitiligo

Published:2024-07-20 Issue:9 Volume: Page:12-16
ISSN:2949-2807
Container-title:Medical alphabet
language:
Short-container-title:Medicinskij alfavit

Author:

Bazhenova E. V.¹^ORCID,Kruglova M. S.²^ORCID

Affiliation:

1. Central State Medical Academy of the Administrative Department of the President of Russia

2. I.M. Sechenov First Moscow State Medical University (Sechenov University)

Abstract

Vitiligo is an autoimmune disease that causes skin depigmentation. The article is a review of the literature with a detailed description of the pathogenesis and the main combinations of therapeutic approaches. The issue of the use of oral and topical janus kinase inhibitors for the treatment of vitiligo was raised.

Publisher

Alfmed LLC

Reference42 articles.

1. Ali Alikhan; Lesley M. Felsten; Meaghan Daly; Vesna Petronic-Rosic (2011). Vitiligo: A comprehensive overview: Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. 65 (3), 0–491.

2. Kundu R. V., Mhlaba J. M., Rangel S. M., Le Poole I. C. The convergence theory for vitiligo: A reappraisal. Exp Dermatol. 2019 Jun; 28 (6): 647–655.

3. Wagner R.Y., Luciani F., Cario-André M., Rubod A., Petit V., Benzekri L., Ezzedine K., Lepreux S., Steingrimsson E., Taieb A., Gauthier Y., Larue L., Delmas V. Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo. J Invest Dermatol. 2015 Jul; 135 (7): 1810–1819.

4. Boukhedouni N., Martins C., Darrigade A.S., Drullion C., Rambert J., Barrault C., Garnier J., Jacquemin C., Thiolat D., Lucchese F., Morel F., Ezzedine K., Taieb A., Bernard F.X., Seneschal J., Boniface K. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight. 2020 Jun 4;5 (11): e133772.

5. Liu H., Wang Y., Le Q., Tong J., Wang H. The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment. Eur J Immunol. 2023 Nov 8: e2250281.